<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937183</url>
  </required_header>
  <id_info>
    <org_study_id>MSCMI-40-2003</org_study_id>
    <secondary_id>CDR0000636859</secondary_id>
    <secondary_id>EU-20913</secondary_id>
    <nct_id>NCT00937183</nct_id>
  </id_info>
  <brief_title>Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma</brief_title>
  <official_title>Vaccination of Lymphoma Patients With Dendritic Cell-lymphoma Cell Hybrids and Dendritic Cells Pulsed With Tumor Lysates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jan Walewski</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as a dendritic cell vaccine made with a patient's
      cancer cells, may stimulate the immune system in different ways and stop cancer cells from
      growing.

      PURPOSE: This phase I/II trial is studying the side effects of dendritic cell vaccine and to
      see how well it works in treating patients with indolent B-cell lymphoma or multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluation of feasibility of dendritic cell (DC)-based vaccination program using
           autologous tumor cells and/or lysates in patients with indolent B cell lymphomas or
           multiple myeloma as an adjuvant therapy to induce immune response in remission after
           cytoreductive treatment.

        -  Evaluation of the immune response of patients treated with this regimen.

        -  Evaluation the progression-free survival of patients treated this regimen.

        -  Evaluate the adverse events of this regimen in these patients.

      OUTLINE: Patients receive intranodal (under ultrasound guidance) or subcutaneous vaccinations
      of adjuvant electrofusion hybrids of autologous dendritic cells (DC) with autologous lymphoma
      cells, electrofusion hybrids of allogeneic DC with autologous lymphoma cells, and/or
      autologous DC pulsed with autologous tumor lysate cells in weeks 0, 2, 4, 8, 12, 18, 26, and
      50.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
  </primary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Mantle cell lymphoma

               -  Marginal zone lymphoma

               -  Follicular lymphoma

               -  Small lymphocytic lymphoma/chronic lymphocytic leukemia

               -  Multiple myeloma

               -  Lymphoplasmacytic lymphoma/Waldenstr√∂m macroglobulinemia

               -  Diffuse large B-cell lymphoma

          -  Adequate sample size and lymphoma cell content in the fresh tissue collected

          -  No bulky or progressive disease

        PATIENT CHARACTERISTICS:

          -  Life expectancy &gt; 3 months

          -  No evidence of lung, heart, liver, or renal failure or severe neurologic disorder

          -  No autoimmune disease or atopic allergy

          -  No HIV positivity

          -  No other malignancy

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Walewski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maria Sklodowska-Curie Institute - Oncology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology - Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maria Sklodowska-Curie Institute - Oncology Center</investigator_affiliation>
    <investigator_full_name>Jan Walewski</investigator_full_name>
    <investigator_title>Head, Dept. of Lymphoid Malignancies</investigator_title>
  </responsible_party>
  <keyword>dendritic cell vaccine</keyword>
  <keyword>tumor cell lysate</keyword>
  <keyword>lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

